Arovella Therapeutics Limited (ALA.AX)
AUD 0.18
(5.88%)
AUD 0.18
(5.88%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 2.05 Million AUD | 21.63% |
| 2023 | 1.69 Million AUD | 5.99% |
| 2022 | 1.59 Million AUD | -6.46% |
| 2021 | 1.7 Million AUD | -33.69% |
| 2020 | 2.57 Million AUD | 13.02% |
| 2019 | 2.27 Million AUD | -56.04% |
| 2018 | 5.17 Million AUD | 63.68% |
| 2017 | 3.16 Million AUD | 8.73% |
| 2016 | 2.9 Million AUD | -17.35% |
| 2015 | 3.52 Million AUD | -19.18% |
| 2014 | 4.35 Million AUD | 7.84% |
| 2013 | 4.03 Million AUD | 47.27% |
| 2012 | 2.74 Million AUD | 9.98% |
| 2011 | 2.49 Million AUD | -29.89% |
| 2010 | 3.55 Million AUD | -54.22% |
| 2009 | 7.76 Million AUD | 39.87% |
| 2008 | 5.55 Million AUD | -16.74% |
| 2007 | 6.67 Million AUD | 103.52% |
| 2006 | 3.27 Million AUD | 1.58% |
| 2005 | 3.22 Million AUD | 14.4% |
| 2004 | 2.82 Million AUD | 218.6% |
| 2003 | 885.33 Thousand AUD | 505.38% |
| 2002 | 146.24 Thousand AUD | 3974.81% |
| 2001 | 3589.00 AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 2.05 Million AUD | 0.0% |
| 2024 Q2 | 2.19 Million AUD | 0.48% |
| 2024 FY | 2.05 Million AUD | 21.63% |
| 2024 Q3 | 2.05 Million AUD | -6.3% |
| 2024 Q1 | 2.18 Million AUD | 36.92% |
| 2023 Q2 | 1.6 Million AUD | 0.46% |
| 2023 Q3 | 1.68 Million AUD | 4.92% |
| 2023 Q4 | 1.59 Million AUD | -5.13% |
| 2023 FY | 1.69 Million AUD | 5.99% |
| 2023 Q1 | 1.59 Million AUD | -0.0% |
| 2022 Q1 | 3.1 Million AUD | 81.77% |
| 2022 FY | 1.59 Million AUD | -6.46% |
| 2022 Q4 | 1.59 Million AUD | 0.0% |
| 2022 Q3 | 1.59 Million AUD | -48.54% |
| 2022 Q2 | 3.1 Million AUD | 0.0% |
| 2021 Q1 | 1.56 Million AUD | -39.17% |
| 2021 Q4 | 1.7 Million AUD | 0.0% |
| 2021 Q3 | 1.7 Million AUD | 9.01% |
| 2021 FY | 1.7 Million AUD | -33.69% |
| 2021 Q2 | 1.56 Million AUD | 0.0% |
| 2020 Q2 | 1.82 Million AUD | 0.0% |
| 2020 Q3 | 2.57 Million AUD | 41.14% |
| 2020 FY | 2.57 Million AUD | 13.02% |
| 2020 Q4 | 2.57 Million AUD | 0.0% |
| 2020 Q1 | 1.82 Million AUD | -19.92% |
| 2019 Q3 | 2.27 Million AUD | 6.89% |
| 2019 Q2 | 2.12 Million AUD | 0.0% |
| 2019 FY | 2.27 Million AUD | -56.04% |
| 2019 Q1 | 2.12 Million AUD | -58.88% |
| 2019 Q4 | 2.27 Million AUD | 0.0% |
| 2018 Q1 | 3.62 Million AUD | 14.59% |
| 2018 Q2 | 3.62 Million AUD | 0.0% |
| 2018 Q4 | 5.17 Million AUD | 0.0% |
| 2018 Q3 | 5.17 Million AUD | 42.84% |
| 2018 FY | 5.17 Million AUD | 63.68% |
| 2017 Q3 | 3.16 Million AUD | -4.07% |
| 2017 FY | 3.16 Million AUD | 8.73% |
| 2017 Q4 | 3.16 Million AUD | 0.0% |
| 2017 Q2 | 3.29 Million AUD | 0.0% |
| 2017 Q1 | 3.29 Million AUD | 13.34% |
| 2016 Q4 | 2.9 Million AUD | 0.0% |
| 2016 Q1 | 3.09 Million AUD | -12.05% |
| 2016 Q3 | 2.9 Million AUD | -6.03% |
| 2016 Q2 | 3.09 Million AUD | 0.0% |
| 2016 FY | 2.9 Million AUD | -17.35% |
| 2015 Q2 | 3.71 Million AUD | 0.0% |
| 2015 FY | 3.52 Million AUD | -19.18% |
| 2015 Q4 | 3.52 Million AUD | 0.0% |
| 2015 Q3 | 3.52 Million AUD | -5.35% |
| 2015 Q1 | 3.71 Million AUD | -14.61% |
| 2014 FY | 4.35 Million AUD | 7.84% |
| 2014 Q2 | 4.71 Million AUD | 0.0% |
| 2014 Q3 | 4.35 Million AUD | -7.69% |
| 2014 Q1 | 4.71 Million AUD | 16.82% |
| 2014 Q4 | 4.35 Million AUD | 0.0% |
| 2013 Q2 | 3.93 Million AUD | 0.0% |
| 2013 Q3 | 4.03 Million AUD | 2.76% |
| 2013 Q4 | 4.03 Million AUD | 0.0% |
| 2013 FY | 4.03 Million AUD | 47.27% |
| 2013 Q1 | 3.93 Million AUD | 43.32% |
| 2012 Q4 | 2.74 Million AUD | 0.0% |
| 2012 FY | 2.74 Million AUD | 9.98% |
| 2011 FY | 2.49 Million AUD | -29.89% |
| 2011 Q4 | 2.49 Million AUD | 0.0% |
| 2010 FY | 3.55 Million AUD | -54.22% |
| 2010 Q4 | 3.55 Million AUD | 0.0% |
| 2009 FY | 7.76 Million AUD | 39.87% |
| 2009 Q4 | 7.76 Million AUD | 0.0% |
| 2008 Q4 | 5.55 Million AUD | 0.0% |
| 2008 FY | 5.55 Million AUD | -16.74% |
| 2007 Q4 | 6.67 Million AUD | 0.0% |
| 2007 FY | 6.67 Million AUD | 103.52% |
| 2006 FY | 3.27 Million AUD | 1.58% |
| 2006 Q4 | 3.27 Million AUD | 0.0% |
| 2005 FY | 3.22 Million AUD | 14.4% |
| 2005 Q4 | 3.22 Million AUD | 0.0% |
| 2004 FY | 2.82 Million AUD | 218.6% |
| 2004 Q4 | 2.82 Million AUD | 0.0% |
| 2003 Q4 | 885.33 Thousand AUD | 0.0% |
| 2003 FY | 885.33 Thousand AUD | 505.38% |
| 2002 FY | 146.24 Thousand AUD | 3974.81% |
| 2001 FY | 3589.00 AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 51.37% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -570.244% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 78.019% |
| Biome Australia Limited | 5.37 Million AUD | 61.725% |
| Patrys Limited | 691.36 Thousand AUD | -197.475% |
| Orthocell Limited | 22.08 Million AUD | 90.687% |
| Imugene Limited | 33.14 Million AUD | 93.795% |
| Noxopharm Limited | 1.28 Million AUD | -59.601% |
| PYC Therapeutics Limited | 10.18 Million AUD | 79.805% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 83.936% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 11.564% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -26.49% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -75.622% |
| CSL Limited | 27.88 Billion AUD | 99.993% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -458.192% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 92.684% |
| Starpharma Holdings Limited | 8.69 Million AUD | 76.355% |
| Nanollose Limited | 465.64 Thousand AUD | -341.677% |
| Memphasys Limited | 5.59 Million AUD | 63.224% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -376.481% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -2300.285% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 39.984% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 44.893% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -96.69% |
| Race Oncology Limited | 1.91 Million AUD | -7.316% |
| Nyrada Inc. | 855.63 Thousand AUD | -140.364% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.175% |
| Dimerix Limited | 13.89 Million AUD | 85.197% |
| PharmAust Limited | 896.6 Thousand AUD | -129.38% |
| Immutep Limited | 10.97 Million AUD | 81.269% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 75.316% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 62.094% |
| BTC Health Limited | 203.94 Thousand AUD | -908.412% |
| Acrux Limited | 5.68 Million AUD | 63.836% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 95.191% |
| Biotron Limited | 737.5 Thousand AUD | -178.863% |
| Tissue Repair Ltd | 1.35 Million AUD | -52.241% |
| AdAlta Limited | 3.54 Million AUD | 41.945% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 95.397% |
| Hexima Limited | 248.67 Thousand AUD | -727.054% |
| AnteoTech Limited | 4.07 Million AUD | 49.534% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 42.622% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 87.06% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -118.433% |
| Actinogen Medical Limited | 1.61 Million AUD | -27.317% |
| Immuron Limited | 2.84 Million AUD | 27.597% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 15.25% |